Merck & Co
Latest statistics and disclosures from Merck & Co's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRNA, PSNL, KYMR, Entrada Therapeutics, Eikon Therapeutics, and represent 88.89% of Merck & Co's stock portfolio.
- Added to shares of these 4 stocks: Eikon Therapeutics (+$18M), Aktis Oncology (+$17M), Xilio Therapeutics, HURA.
- Started 3 new stock positions in Xilio Therapeutics, Eikon Therapeutics, Aktis Oncology.
- Reduced shares in these 1 stock: XLO.
- Sold out of its position in XLO.
- Merck & Co was a net buyer of stock by $35M.
- Merck & Co has $349M in assets under management (AUM), dropping by 26.48%.
- Central Index Key (CIK): 0000310158
Tip: Access up to 7 years of quarterly data
Positions held by Merck & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Merck & Co
Merck & Co holds 14 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moderna (MRNA) | 33.6 | $117M | 2.3M | 50.80 |
|
|
| Personalis Ord (PSNL) | 25.6 | $90M | 14M | 6.37 |
|
|
| Kymera Therapeutics (KYMR) | 18.4 | $64M | 772k | 83.29 |
|
|
| Entrada Therapeutics | 6.3 | $22M | 1.7M | 12.62 |
|
|
| Eikon Therapeutics | 5.0 | $18M | NEW | 1.7M | 10.58 |
|
| Aktis Oncology | 4.9 | $17M | NEW | 953k | 17.89 |
|
| Alector (ALEC) | 2.2 | $7.6M | 3.5M | 2.15 |
|
|
| Sutro Biopharma | 1.9 | $6.8M | 272k | 24.91 |
|
|
| Evaxion Biotech A/s Sponsored Ads | 1.3 | $4.5M | 1.2M | 3.72 |
|
|
| Miragen Therapeutics (VRDN) | 0.5 | $1.8M | 93k | 19.56 |
|
|
| Xilio Therapeutics | 0.3 | $891k | NEW | 106k | 8.41 |
|
| Carisma Therapeutics (CARM) | 0.0 | $48k | 1.5M | 0.03 |
|
|
| Neuphoria Therapeutics (NEUP) | 0.0 | $41k | 10k | 4.07 |
|
|
| Tuhura Biosciences (HURA) | 0.0 | $35k | +39% | 19k | 1.79 |
|
Past Filings by Merck & Co
SEC 13F filings are viewable for Merck & Co going back to 2025
- Merck & Co 2026 Q1 filed May 13, 2026
- Merck & Co 2025 Q4 filed Feb. 17, 2026
- Merck & Co 2025 Q3 filed Nov. 12, 2025
- Merck & Co 2025 Q2 filed Aug. 13, 2025